SXI Life Sciences
7.099,32
PKT
+70,81
PKT
+1,01
%
Werbung
Analysen zu SXI Life Sciences-Werten
Datum | Rating | Analyst | |
---|---|---|---|
07.04.20 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
07.04.20 | Novartis Underweight | JP Morgan Chase & Co. | |
06.04.20 | Novartis Hold | Deutsche Bank AG | |
06.04.20 | Roche buy | Deutsche Bank AG | |
03.04.20 | Roche overweight | Barclays Capital | |
02.04.20 | Novartis Conviction Buy | Goldman Sachs Group Inc. | |
01.04.20 | Roche overweight | JP Morgan Chase & Co. | |
01.04.20 | Novartis buy | Jefferies & Company Inc. | |
31.03.20 | Novartis buy | Oddo BHF | |
31.03.20 | Roche buy | Oddo BHF | |
30.03.20 | Roche overweight | JP Morgan Chase & Co. | |
24.03.20 | Roche buy | UBS AG | |
24.03.20 | Novartis Underweight | JP Morgan Chase & Co. | |
20.03.20 | Novartis Hold | Deutsche Bank AG | |
20.03.20 | Roche buy | Deutsche Bank AG | |
17.03.20 | Roche overweight | Barclays Capital | |
17.03.20 | Novartis Underweight | Barclays Capital | |
13.03.20 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
11.03.20 | Novartis Equal-Weight | Morgan Stanley | |
11.03.20 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
09.03.20 | Roche overweight | JP Morgan Chase & Co. | |
03.03.20 | Roche overweight | Morgan Stanley | |
26.02.20 | Novartis Hold | Deutsche Bank AG | |
25.02.20 | Novartis Underweight | Barclays Capital | |
25.02.20 | Novartis buy | Jefferies & Company Inc. | |
25.02.20 | Novartis Neutral | UBS AG | |
20.02.20 | Roche overweight | Barclays Capital | |
20.02.20 | Roche buy | Goldman Sachs Group Inc. | |
18.02.20 | Roche overweight | Morgan Stanley | |
10.02.20 | Roche buy | Jefferies & Company Inc. | |
07.02.20 | Roche buy | UBS AG | |
06.02.20 | Roche overweight | JP Morgan Chase & Co. | |
04.02.20 | Roche buy | Deutsche Bank AG | |
03.02.20 | Roche overweight | JP Morgan Chase & Co. | |
31.01.20 | Roche Neutral | Credit Suisse Group | |
31.01.20 | Novartis Hold | Deutsche Bank AG | |
31.01.20 | Roche buy | Deutsche Bank AG | |
30.01.20 | Novartis Neutral | Credit Suisse Group | |
30.01.20 | Roche overweight | Barclays Capital | |
30.01.20 | Roche buy | UBS AG |